TABLE 3.
Selected recent active PDT studies for malignant diseases obtained from ClinicalTrials.gov database.
| Title | Status | Cancer type | Photosensitizer | Excitation wavelength | Phase | Start date | ClinicalTrials.gov identifier |
|---|---|---|---|---|---|---|---|
| Study to evaluate the safety and efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the treatment of superficial basal cell carcinoma (sBCC) with photodynamic therapy (PDT) | Recruiting | Basal cell carcinoma | ALA-PDT (Ameluz®-PDT) | 635 nm | Phase 3 | September 25, 2018 | NCT03573401 |
| Use of jet-injection in photodynamic therapy for basal cell carcinoma | Recruiting | Basal cell carcinoma | Jet-injection (AirGent2.0) of ALA (levulan kerastick) | 400–450 nm | Phase 2 | September 9, 2020 | NCT04552990 |
| Intravesical photodynamic therapy (PDT) in BCG refractory/Intolerant non-muscle invasive bladder cancer (NMIBC) patients | Recruiting | Bladder cancer | TLD-1433 (Ru(II) polypyridyl complex) | 520–540 nm | Phase 2 | August 30, 2019 | NCT03945162 |
| PCI treatment/Gemcitabine & chemotherapy vs chemotherapy alone in patients with inoperable extrahepatic bile duct cancer | Recruiting | Cholangiocarcinoma | Fimaporfin | 435 nm | Phase 2 | May 23, 2019 | NCT04099888 |
| A trial of a new type of photodynamic therapy (VTP) in the treatment of patients with cancer of the esophagus who have trouble swallowing | Recruiting | Esophagogastric cancer | WST11-mediated vascular-targeted photodynamic therapy (VTP) | 753 nm | Phase 1 | April 26, 2017 | NCT03133650 |
| Intraoperative photodynamic therapy of glioblastoma | Active, not recruiting | Glioblastoma | Gliolan® (5-ALA- PpIX (protoporhyrin IX)) | 400–410 nm | Not applicable | May 5, 2017 | NCT03048240 |
| Stereotactical photodynamic therapy with 5-aminolevulinic acid (Gliolan®) in recurrent glioblastoma | Recruiting | Glioblastoma | Gliolan® (5-ALA- PpIX (protoporhyrin IX)) | 400–410 nm | Phase 2 | March 2021 | NCT04469699 |
| Porfimer sodium interstitial photodynamic therapy with or without standard of care chemotherapy in treating patients with locally advanced or recurrent head and neck cancer | Recruiting | Head and neck carcinoma | Porfimer sodium (Photofrin®) | 630 nm | Phase 2 | January 16, 2019 | NCT03727061 |
| Endobronchial ultrasound guided interstitial photodynamic therapy in treating patients with locally advanced lung cancer | Recruiting | Lung carcinoma | Porfimer sodium (Photofrin®) | 630 nm | Early phase 1 | February 4, 2020 | NCT03735095 |
| Photodynamic therapy for prevention of nonmelanoma skin cancer in organ transplant recipients | Recruiting | Nonmelanoma skin cancers | ALA (levulan kerastick) | 400–450 nm | Not applicable | February 2016 | NCT02751151 |
| Photodynamic therapy with HPPH compared to standard of care surgery in treating patients with oral cavity cancer | Active, not recruiting | Oral cavity squamous cell carcinoma | HPPH (photochlor) (2–1 [heyloxyethyl]-2-devinylpyropheophorbide-a) | 665 nm | Phase 2 | March 30, 2017 | NCT03090412 |
| Ultrasound-guided verteporfin photodynamic therapy for the treatment of unresectable solid pancreatic tumors or advanced pancreatic cancer, VERTPAC-02 study | Recruiting | Pancreatic carcinoma | Verteporfin | 690 nm | Phase 2 | December 6, 2016 | NCT03033225 |
| Study of the efficacy, safety and quality of life after TOOKAD® soluble (VTP) for intermediate risk prostate cancer | Active, not recruiting | Prostate cancer | TOOKAD® soluble VTP | 753 nm | Phase 2 | October 2, 2017 | NCT03315754 |
| Study of erectile dysfunction, urinary incontinence and related QoL after TOOKAD® VTP for low risk prostate cancer | Active, not recruiting | Prostate cancer | TOOKAD® soluble VTP | 753 nm | Phase 4 | January 21, 2019 | NCT03849365 |
| Clinical study to assess the safety and adequacy of effectiveness of the SpectraCure P18 system | Recruiting | Prostate cancer | Verteporfin | 690 nm | Phase 1 | March 21, 2017 | NCT03067051 |
| HS-201, an HSP90 inhibitor-linked verteporfin for detection of solid malignancies | Recruiting | Solid tumor | HS-201 (verteporfin-tethered HSP90 inhibitor) | 690 nm | Phase 1 | July 15, 2020 | NCT03906643 |
| Phase I study in advanced malignancies | Recruiting | Solid tumor | ALA (5-aminolevulinic acid) | 635 nm | Phase 1 | July 23, 2020 | NCT04381806 |
| Treatment of tumors in the urinary collecting system of the kidney or ureter using a light activated drug (WST11) | Recruiting | Upper tract urothelial carcinoma | WST11 | 753 nm | Phase 1 | August 1, 2018 | NCT03617003 |